Ilaris, which was listed for reimbursement 9 years after receiving marketing authorization in Korea, can now be prescribed at general hospitals in Korea.

According to industry sources, Novartis Korea's hereditary recurrent fever syndrome drug Ilaris (canakinumab) has passed the drug committees (DCs) of Seoul National University Hospital, Seoul St Mary's Hospital, and Sinchon Severance Hospital.

Ilaris, which was approved in Korea in 2015, has been on the reimbursement list since August. The company quickly accepted the conditional reimbursement decision made by the MFDS’s Drug Reimbursement Evaluation Committee in April and then promptly concluded the difficult drug pricing negotiation